Ind Swift Stock Price Today (NSE: INDSWFTLTD)
Fundamental Score
Ind Swift Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ind Swift share price today is ₹15.76, up +0.00% on NSE/BSE as of 22 June 2026. Ind Swift (INDSWFTLTD) is a Small-cap company in the Pharmaceuticals & Biotechnology sector with a market capitalisation of ₹92.30 (Cr). The 52-week high for INDSWFTLTD share price is ₹19.90 and the 52-week low is ₹14.71. At a P/E ratio of 11.80x, INDSWFTLTD is currently trading below its industry average P/E of 33.56x.
Ind Swift Share Price Chart — NSE/BSE Historical Performance
Ind Swift share price chart: -4.31% return over the past month. 52-week high ₹19.90, 52-week low ₹14.71.
Ind Swift — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹15.16 | ₹17.82 | ₹15.15 | ₹15.76 | 6.45L (Cr) | |
| ₹14.80 | ₹15.47 | ₹14.80 | ₹14.85 | 74.51K (Cr) | |
| ₹15.99 | ₹15.99 | ₹14.71 | ₹14.96 | 57.87K (Cr) | |
| ₹15.75 | ₹15.83 | ₹15.31 | ₹15.47 | 24.37K (Cr) | |
| ₹16.15 | ₹16.15 | ₹15.41 | ₹15.49 | 41.11K (Cr) | |
| ₹16.56 | ₹16.56 | ₹15.87 | ₹15.96 | 42.91K (Cr) | |
| ₹16.60 | ₹16.85 | ₹16.27 | ₹16.36 | 36.41K (Cr) | |
| ₹16.35 | ₹16.89 | ₹16.35 | ₹16.45 | 22.58K (Cr) | |
| ₹16.70 | ₹17.29 | ₹16.40 | ₹16.65 | 55.13K (Cr) | |
| ₹16.50 | ₹16.94 | ₹16.50 | ₹16.71 | 55.15K (Cr) |
Ind Swift — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹16.70 | ₹17.82 | ₹14.71 | ₹15.76 | -5.63% | |
| ₹17.92 | ₹19.76 | ₹15.65 | ₹16.71 | -6.75% | |
| ₹15.58 | ₹19.90 | ₹15.12 | ₹17.77 | +14.06% |
AI Research Briefing
Powered by Gemini · 2026-04-20
Micro-cap formulations play hoping for a turnaround; Q4 results are the acid test.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Ind-Swift Laboratories (INDSWFTLAB) share price has experienced volatility. It hit a 52-week high of earlier in April but has since declined, This decline includes a significant drop of around 8.98% in a single session. The company clarified that it is unaware of specific reasons for a recent surge in its share trading volume, attributing it to market conditions. Ind-Swift Laboratories is set to announce its Q4 FY26 results on May 12, 2026.
CORE STORY (THE REAL GAME)
Ind-Swift is now a formulations play after divesting its API business in March 2024 for The market is trying to figure out if the remaining business can justify the valuation, especially given the increased focus on innovation and value-added products in the Indian pharma sector.
- Upcoming Q4 FY26 results on May 12, 2026
- Recent price volatility and a drop below the 50-day SMA
- Clarification sought by exchange regarding volume surge
- Positive Q4 results and strong FY27 guidance
- Significant order wins in the formulations business
- Government incentives for pharmaceutical manufacturing
- Micro/SME cap: Liquidity risk is high
- Latest Qtr YoY Profit: -131.15%
- Dependence on market conditions for volume surges
No significant change in FII/DII/Promoter holdings.
Indian pharma sector is transitioning towards innovation-led growth.
Free Cash Flow 5Y: ₹97.74 Cr
Next 3-6 months depend on Q4 results and management commentary. Focus will be on formulations business growth and margin improvement.
Primary Thesis Risk
Inability to scale formulations business post API divestment.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ind Swift Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ind Swift Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDSWFTLTD across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 11.80 vs Industry: 33.56)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (18.19% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.19% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Cash Generation (₹97.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (55.58%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-131.15%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (1.20x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ind Swift vs Pharmaceuticals & Biotechnology Peers
Peer Comparison - Pharmaceuticals & Biotechnology
Compare Ind Swift with 1 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ind SwiftInd Swift...Selected✓ INDSWFTLTD • 524652 | 45.8/100 | ₹15.76₹16 | ₹92.30₹92.30 | 11.80Average 11.8 Average | — — | 11.86%Average 11.86% Average | — — | 18.19%Excellent 18.19% Excellent | 9.35%Good 9.35% Good | 0.00% |
Adline Chem Lab LtdAdline Chem Lab... ADLINE • 524604 | 14.1/100 | ₹13.70₹14 | ₹4.91₹4.91 | — — | — — | — — | — — | 14.49%Good 14.49% Good | — — | 0.00% |
Ind Swift PE Ratio History
Historical price-to-earnings ratio for INDSWFTLTD — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹52.33 | ₹15.76 | 0.3x |
| FY 2024 | ₹2.63 | ₹33.05 | 12.6x |
| FY 2023 | ₹4.81 | ₹18.20 | 3.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ind Swift Quarterly Performance
Latest quarterly metrics for INDSWFTLTD — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.15%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-131.15%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.35%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.19%
Compounded annual net profit growth over 5 years
Ind Swift Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INDSWFTLTD — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ind Swift Financial Statements
Annual income statement, balance sheet and cash flow for Ind Swift (INDSWFTLTD) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ind Swift
About INDSWFTLTD (Ind Swift)
Ind Swift is a dynamic and multifaceted pharmaceutical and biotechnology company operating at the forefront of healthcare innovation. With a steadfast commitment to improving globa...l health outcomes, Ind Swift engages in the comprehensive development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products. The company's core strength lies in its ability to seamlessly integrate cutting-edge research and development with advanced manufacturing capabilities, allowing it to deliver high-quality, accessible medicines to patients worldwide. Ind Swift's unwavering dedication to excellence, coupled with its strong ethical values, has solidified its position as a trusted partner in the healthcare industry. The company's robust product line encompasses a wide spectrum of therapeutic areas, addressing critical healthcare needs across various medical specialties. Ind Swift meticulously formulates and produces a range of pharmaceutical solutions, including finished dosage forms, active pharmaceutical ingredients (APIs), and specialized herbal remedies. This comprehensive approach allows the company to cater to a diverse range of patient populations and medical conditions. Ind Swift's commitment to innovation is reflected in its continuous pursuit of novel drug delivery systems and therapeutic advancements, aimed at enhancing treatment efficacy and improving patient compliance. The therapeutic products span from areas like pain management to women's health. Ind Swift's unwavering focus on quality and regulatory compliance underscores its commitment to patient safety and product integrity. The company adheres to stringent international standards in all aspects of its operations, from research and development to manufacturing and distribution. Through rigorous quality control measures and continuous improvement initiatives, Ind Swift ensures that its products meet the highest standards of efficacy, safety, and purity. This unwavering dedication to quality has earned the company the trust of healthcare professionals and patients alike, solidifying its reputation as a reliable provider of pharmaceutical solutions.
Company Details
Key Leadership
INDSWFTLTD Share Price: Frequently Asked Questions
What is the current share price of Ind Swift?
Ind Swift (INDSWFTLTD) trades at ₹15.76 on NSE and BSE. Market cap ₹92.30 (Cr). Educational data only.
What is the P/E ratio of Ind Swift?
Ind Swift has a P/E of 11.80x vs industry average 33.56x.
What is the Bull Run score for Ind Swift?
Ind Swift has a Bull Run score of 45.8/100 based on 25+ financial parameters.
Does Ind Swift pay dividends?
Ind Swift has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ind Swift?
Ind Swift has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ind Swift?
Ind Swift has debt-to-equity of N/A.
Is Ind Swift a good investment?
Bull Run gives Ind Swift a score of 45.8/100. This is not investment advice — consult a SEBI-registered advisor.